Cingulate is a clinical stage biopharmaceutical company focused on the development of innovative new product candidates for the treatments of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety …

Shane J. Schaffer, PharmD is a Co-Founder of Cingulate Therapeutics and has served as the CEO since its inception. Dr. Schaffer is a 25-year pharmaceutical industry veteran with experience in …

Jun 28, 2024 · With an initial focus on the treatment of attention deficit/hyperactivity disorder (ADHD), Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be …

The Investor Relations website contains information about Cingulate Inc's business for stockholders, potential investors, and financial analysts.

Dec 15, 2025 · Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Oct 23, 2025 · Cingulate’s lead candidate, CTx-1301, is in late-stage development for ADHD, with additional candidates in anxiety and other neuropsychiatric indications. Cingulate is headquartered in …

Nov 7, 2024 · KANSAS CITY, Kan., June 25, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) …

Cingulate INC SEC filing: Form 8-K on 01/29/2024 (0001493152-24-004061).

Nov 10, 2025 · Cingulate’s lead candidate, CTx-1301, is in late-stage development for ADHD, with additional candidates in anxiety and other neuropsychiatric indications. Cingulate is headquartered in …

Study was funded by Cingulate Therapeutics LLC: 1901 W. 47th Pl, Westwood, KS 66205 913-942-2300; [email protected] Poster Presented at The American Professional Society of …